Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

97.19 +1.64 (+1.72%)
Streaming Delayed Price Updated: 2:49 PM EDT, Apr 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 502,489
Open 95.76
Bid (Size) 97.14 (1,500)
Ask (Size) 97.23 (100)
Prev. Close 95.55
Today's Range 95.76 - 97.81
52wk Range 56.13 - 112.29
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INCYTE CORP (NASDAQ:INCY) Presents a High-Growth Momentum Breakout Setup ↗
Incyte Corp (INCY) shows strong earnings growth and a positive technical setup, suggesting a potential breakout for momentum investors. 
Via Chartmill
News headline image
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire

Performance

YTD
-4.2%
-4.2%
1 Month
+4.5%
+4.5%
3 Month
-8.6%
-8.6%
6 Month
+14.7%
+14.7%
1 Year
+64.1%
+64.1%

More News

Read More
News headline image
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
From Adagene Inc.
Via GlobeNewswire
Incyte Corp (NASDAQ:INCY) Presents a Compelling Value Case with Strong Fundamentals ↗
Via Chartmill
News headline image
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
News headline image
Incyte Announces Executive Leadership Appointments
From Incyte
Via Business Wire
News headline image
2 Growth Stocks with Explosive Upside and 1 We Avoid
Via StockStory
News headline image
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
News headline image
1 Cash-Heavy Stock to Target This Week and 2 Facing Headwinds
Via StockStory
News headline image
2 Value Stocks to Consider Right Now and 1 We Ignore
Via StockStory
News headline image
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings?
Via StockStory
Topics Stocks
News headline image
Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer ↗
Via Stocktwits
News headline image
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
From Incyte
Via Business Wire
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Avoid
Via StockStory
News headline image
3 S&P 500 Stocks to Target This Week
Via StockStory
Topics Stocks
News headline image
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Question
Via StockStory
News headline image
Registration Momentum Builds Across the Oncology Pipeline
From USA News Group
Via GlobeNewswire
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
The Top 5 Analyst Questions From Incyte’s Q4 Earnings Call
Via StockStory
Topics Earnings
News headline image
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
Via Finterra
Topics Economy Intellectual Property
News headline image
INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow
Via StockStory

Frequently Asked Questions

Is Incyte Corporation - Common Stock publicly traded?
Yes, Incyte Corporation - Common Stock is publicly traded.
What exchange does Incyte Corporation - Common Stock trade on?
Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Incyte Corporation - Common Stock?
The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
What is the current price of Incyte Corporation - Common Stock?
The current price of Incyte Corporation - Common Stock is 97.19
When was Incyte Corporation - Common Stock last traded?
The last trade of Incyte Corporation - Common Stock was at 04/14/26 02:49 PM ET
What is the market capitalization of Incyte Corporation - Common Stock?
The market capitalization of Incyte Corporation - Common Stock is 21.62B
How many shares of Incyte Corporation - Common Stock are outstanding?
Incyte Corporation - Common Stock has 22B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.